Please use this identifier to cite or link to this item:
|Title:||Intraocular pressure-lovering effect and safety of travoprost 0.004% and latanoprost 0.005% for the treatment of chronic angle closure glaucoma|
|Authors:||Chew, P.T.K. |
|Source:||Chew, P.T.K., Pongpun, P.R., Euswas, A., Lu, D.-W., Chua, J., Hui, S.-P., Rait, J., Goldberg, I., Li, B. (2006-02). Intraocular pressure-lovering effect and safety of travoprost 0.004% and latanoprost 0.005% for the treatment of chronic angle closure glaucoma. Asian Journal of Ophthalmology 8 (1) : 13-19. ScholarBank@NUS Repository.|
|Abstract:||Aim: To compare the intraocular pressure-lowering efficacy and safety of travoprost 0.004% with latanoprost 0.005% for patients with chronic angle closure glaucoma. Patients and methods: 320 patients with chronic angle closure glaucoma, who had previously undergone laser peripheral iridotomy, were randomised to receive travoprost 0.004% once daily (n = 161) or latanoprost 0.005% (n = 159) once daily for 12 weeks. Efficacy and safety evaluations were conducted on day 2, and weeks 2, 6, and 12. Intraocular pressure measurements were performed at 9.00 am and 4.00 pm, except at the week 6 visit, when the intraocular pressure was measured at 9.00 am only. Results: Mean intraocular pressure reductions from baseline were up to 9.1 mm Hg (95% confidence interval, -9.7, -8.4) and 7.9 mm Hg (95% confidence interval, -8.5, -7.3) with travoprost and latanoprost, respectively. Pooled intraocular pressure data for the 12-week period suggested that travoprost was more efficacious than latanoprost at 9.00 am, but this was not statistically significant. At 4.00 pm, pooled intraocular pressure data for the intent-to-treat analysis demonstrated a statistically superior reduction for travoprost compared with latanoprost (p = 0.0196). Travoprost 0.004% also demonstrated significantly greater intraocular pressure reduction from baseline than latanoprost in the per protocol analysis at 4.00 pm (p = 0.0162). Up to 71% of patients treated with travoprost and up to 63% of patients treated with latanoprost achieved a target intraocular pressure of|
|Source Title:||Asian Journal of Ophthalmology|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 14, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.